Thank you for submitting your manuscript for consideration by The EMBO Journal. It has now been seen by three referees whose comments to the authors are shown below. As you will see from their reports the referees consider the study as being an interesting and potentially important one in principle. Still, they all feel strongly that the evidence presented needs to be strengthened considerably before they can support publication of the manuscript here -in particular as your findings directly oppose an earlier paper published by another laboratory. They all come up with a number of additional controls which could help to make your case more convincing, and it is also pointed out that the differences/conflicts with the Pique et al paper should be put forward in an a bit mildened tone.
Clearly, given the case you are making against the Pique et al paper it is essential that the present paper puts forward strong and unequivocal data to settle the case and to avoid further confusion in the field. From the referees' reports it becomes clear that this condition has not been fulfilled yet. We will therefore be able to consider a revised version of the manuscript only under the condition that you can strengthen the study considerably to the full satisfaction of the referees. I would like to add that figure 3, panel C should be replaced by a replicate experiment where all relevant lanes are run on the same gel in the relevant order as also pointed out by referee 2. Furthermore, you may wish to consider modifying the title to a more "positive" message such as "Musashi controls early translational activation of cyclin B5 mRNA, independently of CPEs" (suggestion of referee 3 to the editor). Also, it would be good if you could milden the tone when referring to the Pique et al. paper.
I should remind you that it is EMBO Journal policy to allow a single round of revision only and that, therefore, acceptance or rejection of the manuscript will depend on the completeness of your responses included in the next, final version of the manuscript as well as on the final assessment by the referees.
Thank you for the opportunity to consider your work for publication. I look forward to your revision.
Yours sincerely, Editor
The EMBO Journal
------------------------------------------------REFEREE COMMENTS
Referee #1 (Remarks to the Author):
Based on the previous work by the authors and the data presented here, the authors challenge the recent model presented in Cell that focuses almost entirely exclusively on the roles of CPEs in determining early via late polyadenylation. The data presented here (and previously) do raise legitimate concerns over the recently presented model, and provide an alternative model to explain the temporal control. While the data are in general convincing and of high quality, there are a number of points that should be addressed. Fig.2A the data here from S1B-this will avoid confusion that CPEs do not even mediate late polyadenylation.
(ii) The most striking effect in Fig 2 - is the reduction of the MBE mutant translation in nonprogesterone treated oocytes-this implies a role for MBE in activation/stimulating translation in stage VI oocytes. This would generally be considered not to be a polyadenylation event but in Fig  S4 the globin 3'UTR with either a MBE or a TCS appears to be adenylated prior to progesterone. Can the authors resolve this issue, and is this stimulation in stage VI due to polyadenylation. (iii) An AAGAAA mutant should be included to show that the small effects on the MBE mutant translation (stage VI and plus progesterone) are due to polyadenylation. Can quantitation of the fold effect on translation be added into the text corresponding to this figure, as the differences in basal translation make it hard to compare the fold activation of MBE versus wild-type in response to progesterone.
Figure 3/4: (i) The dual effect of Msl1/2 knock-down appears surprising given the Msl1 is only reduced by 1/5th and the proteins have been shown to be unable to completely complement one another. Can the authors comment on this. Is this the reason that they propose that the small amount of newly synthesised msl1 is responsible for triggered adenylation-as levels remain close to a steep threshold? (ii) CPEB levels in these experiments are increasing at level equal to or perhaps exceeding the changes in Musashi levels. This potential complications for dissecting the effects of Musashi versus CPEB should be discussed, given that CPEB levels have been widely touted to play a role in early versus late polyadenylation. Could the dominant negative form of Musashi, or CPEB overexpression (in the absence of musashi depletion) be used to further clarify this point ?? (iii) In figure 4 please include AAGAAA to show effects are dependent on polyadenylation as well as musashi. Is an alternative explanation of the inability of cyclin B-delta87 mutant to rescue polyadenylation of B5 and B2 not the rationale for the experiment -that the effect reflects in part " knockdown on general mRNA translational activation" (p11). Can data be provided to rule this out.
Given the controversy surrounding the roles of CPEs and MBEs in early events -can an additional figure subjecting one of the early MBE containing, CPE absent mRNA previously identified by the authors, to the same analysis, as fig 2-4.
Minor comments:
P4. It should be noted that the definition described here as "artificially contrived" for early and late relates to the original functional definition of class I and II as described by Wickens and colleagues (Mol Biol Cell. 1997 8:1633 . A change of wording may be appropriate -in other words whilst that was the original definition and that also used by the lab of Richter and the lab of Mendez, that an alternative classification is possible. Likewise the language appears rather combative in places, for instance in the introduction, and the beginning of the results and discussion -the data speak clearly without the use of such strong terms.
P5 -please give citations listed after support for CPE-dependent and CPE-independent mechanisms of c-mos activation.
P7 -Pique et al, is not the first to suggest that "CPE position and combinatorial arrangements within mRNA 3'UTRs enforces the timing of mRNA translational activation during oocyte meiotic cell cycle", please reference earlier work by several groups which contributed this idea that the CPE is the major determinant of cytoplasmic polyadenylation or cite a review to reflect this work.
P7-line 7-please change sentence including "timing" to timecourse Can the consensus sequence of an MBE be given with an indication of how often it appears within the 3'UTR compared to other areas of mRNAs.
P16 "musashi protein, newly synthesized in response to progesterone" the data in Fig3C clearly do not support the idea that musashi synthesis triggers polyadenylation-levels barely increase (1.48) in response to progesterone (msl1) and in the case of msl2 decrease. The activation of dormant maternal mRNAs via polyadenylation in early development is a paradigm in the areas of gene expression regulation, translational control, 3' end formation and cell cycle regulation, and of broad interest. The authors extend their previous analyses of the mechanism of translational activation (TA) during meiotic maturation of Xenopus oocytes, and reevaluate an extensive study by the Mendez lab published last year in Cell. They report that the early phase of TA, responsible for mos synthesis for example, is due to the RNA-binding protein Musashi, rather than CPEB. They concur with Mendez that the late phase is due to CPEB.
The ms is on the whole clearly written, though the "anti-Mendez" tone could be lowered somewhat. The data in Figure 1 , and the explanation (albeit incomplete) behind the differences in design of the two studies, make the examination of the earlier report very important and interesting, and not just to a specialised audience. Unfortunately, some of the data here need further verification before a final conclusion can be reached. Fig. 1 The differences in timing of polyadenylation of the different mRNAs are very convincing. The authors go on to examine the effect of mutating the MBE motif in cyclin B5 on luciferase expression (Fig. 2 ), but what is the effect in an experiment like Fig.1 -is the timing delayed? Conversely, if an MBE is inserted into the cyclin B2 UTR, does this lead to premature polyadenylation? After all, the authors make a great distinction between their approach (strictly temporal analysis) and that of Mendez (signaling pathways-though it is never explicitly stated what their precise approach was), and yet the cyclin B5 mutagenesis experiment is only presented in terms of signaling If that is the case (and qRT-PCR could be used to check) then the maturation result could be due to loss of mos, not Msi. Alternatively, the Msi DN construct (Charlesworth et al., 2006) could be used; there did not appear to be any effect on mos RNA levels in that case.
Specific comments
Another problem with the Fig. 3 Msi ablation experiment is the western analysis of the knock-down (panel C). This is unusually set out with apparently different bands taken from different exposures etc such that the tubulin loading controls vary in signal intensity considerably between different "lanes". Also confusing is the annotation of "accumulation" for the Msi bands -for Msi1 it is just about OK with the "-prog" lanes being set to 1 (I assume that's what happened, they don't seem to be of equal intensity), but this is not the case for Msi2. Msi2 appears to be difficult to capture on a western (low abundance/ poor antibody?), is reduced by AS in the absence of progesterone, but then doubles with progesterone -suggesting it is itself translationally actived in eggs or something else? The text on this issue was not clear either.
As this experiment will need repeating -to assess mos RNA levels -a more conventional (eg as panel B) western could be done to verify kd of the two Msi proteins. As the kd is primarily or only of newly-synthesised Msi proteins, then immunoprecipitation of 35S Met labelled oocytes may be more instructive. The data in this paper appear clear and convincing. However, the paper directly opposes a paper published by another leading group in the field in a well respected journal (Pique et al, 2008) . Therefore, to avoid continuing confusion in the field, the results have to be unequivocal.
In order for this clarity to prevail, the following comments should be addressed.
1.In many of the figure legends the authors indicate that an experiment was repeated 2 or 3 times with similar results. This has been common practice in the field, because of the variability in reporter assay results between the oocytes from different animals and collected at different times. However, this is no longer acceptable, and graphs of luciferase activities should either present averages and standard deviations over multiple independent experiments, or multiple experiments should be shown, in the supplementary data if necessary.
2. The knock down of Msi1 and Msi2 looks very convincing. However, to make sure that the oligos are not having off-target effects, restoration of Msi levels by injection of pure protein or a resistant (mouse?) mRNA should be attempted both for maturation and polyadenylation experiments. An additional control could be an independent set of knock down oligos.
3.The authors make case for the mRNAs that lack an MBE but contain CPEs not overlapping with the poly(A) signal to be late polyadenylating, but independent of cdc2 activation and give cyclin B2 as an example. However, they do not show that the cyclin B2 mRNA polyadenylation and translation is cdc2 activation independent in their hands. The result in Fig 4A indicates that this may perhaps not be the case, as cyclin B2 polyadenylation appears to be Msi dependent. There is a possibility that the contrast with the Pique paper is due to for instance differences in the Xenopus strains or their husbandry. It is therefore important to repeat the AS mos knockdown for cyclin B2 polyadenylation and show that the results agree with the findings of Pique et al.
4.The authors should show that their B5 mbm mutant does still bind CPEB and that the B5 CPE mut does not. This could perhaps be most easily achieved by UV crosslinking of the radioactive RNAs to oocyte extract and IP with a CPEB antibody.
5.The paper does not address the evidence that CPEB dominant negative mutants, notably the Nterminal deletion mutant and the S174/180 phoshorylation site mutant, repress oocyte maturation and Mos synthesis (Mendez et al, Nature 404: 302, 2000) , either in the discussion or experimentally. Ideally this should be experimentally addressed, by showing for instance that the dominant negative CPEB affects MBE mediated polyadenylation if CPEs are present in the mRNA.
Minor points: 1.Supplementary figures 1-3 would be better shown in the paper itself. 2.On page 9, second paragraph, 6th line, the mention of "control AS-injected oocytes" does not make sense to me, as no oligos appear to be injected in figure S1B. 3.On page 10, line 6 from the top, Fig. S4 should be Fig. S3 . 4.Page 12, first line "CPEB degradation, an indicator of CPEB activation". This is absolutely not the case and contrary to the conclusion of the cited paper. Partial CPEB degradation appears necessary to overcome the repression of cytoplasmic polyadenylation mediated by a CPE overlapping with the poly(A) signal, activation of CPEB is mediated by phoshorylation on a specific residue. 5.It would be good to know how many of the mRNAs classed as early in the Pique paper contain an MBE or TCS. Enclosed, please find a revised version of our manuscript EMBOJ-2009-70833 that we submit for publication in the EMBO Journal. In response to a reviewer comment, we have retitled the paper "Enforcing temporal control of maternal mRNA translation during oocyte cell cycle progression."
In this revision we provide extensive new data to strengthen and clarify our proposed model and to address critiques raised by the three reviewers. All three reviewers of the original manuscript considered the study important for presenting a complete model of the mechanisms controlling the timing of mRNA translation during Xenopus oocyte meiotic progression. The reviewers felt, however, that the manuscript required additional controls to make the results unequivocal and to prevent continuing confusion in the field. The reviewers also commented that the text was a little combative with regard to differences/conflicts with the previous model presented by Pique et.al (Cell 132:434-448 (2008) ). Our revised title and discussion focuses on presenting a model in which multiple trans-acting factors control the timing of gene expression during cell cycle progression, rather than stressing the weaknesses of a previous model.
We thank the reviewers for the thoughtful insights that have resulted in a greatly improved manuscript. We detail our responses to individual reviewer comments below.
Reviewer 1 Figure 2 : We have performed additional reporter experiments to resolve the variation in relative translation of the Musashi-binding mutant and wild-type reporters in progesterone-stimulated oocytes from different animals. In the revised manuscript we present new data that clearly indicate that activation of the mutant reporter is attenuated during early oocyte cell cycle progression (Figure 2 ). These data are consistent with a role for the Musashi-binding element in directing translational activation of the reporter during early progesterone-stimulated cell cycle progression. We present this data as a quantified fold effect of each reporter in response to progesterone, as requested by the reviewer. We have also included the effect, upon reporter translation, of loss of the polyadenylation hexanucleotide (Hexm). These data are consistent with cyclin B5 reporter translational activation being mediated through MBE-directed polyadenylation. The reviewer commented that the original data might suggest a role for the Musashibinding element (MBE) in stimulating translation in immature oocytes. While it is interesting that Musashi may function in immature oocytes, we feel this is outside the scope of the revised manuscript that is focused on Musashi-directed translational activation in response to progesterone.
Figure 3/4: We acknowledge that the profound effect of the Musashi1/2 antisense (MsiAS) knockdown on progesterone-stimulated GVBD is indeed surprising in view of the limited effect of upon the levels of Musashi protein (Supplemental Figure S6) . We propose that the residual Musashi protein is insufficient to mediate mRNA translational activation. The reviewer is correct that this may represent a "threshold" effect or may reflect the need for newly synthesized (rather than pre-existing) Musashi protein. We have modified the text to reflect these possibilities. The mechanistic basis of the progesterone-stimulated increase in Musashi protein (previous Figure 3C) is not directly addressed in this study. To avoid further complicating an already complex model, we have deleted the data of progesterone induced Musashi levels from Figure 3 . The question posed by the reviewer on the role of CPEB in Msi AS-treated oocytes is particularly germane to this study and is experimentally addressed in the revised manuscript. As shown in Figure 3 , Msi AS treatment does not affect endogenous CPEB levels. Furthermore, new data demonstrate that expression of exogenous CPEB protein does not rescue GVBD in Msi AS-treated oocytes (revised Figure 4) . These findings indicate that CPEB does not mediate activation of mRNA translation in the absence of Musashi function. By contrast, expression of exogenous Musashi rescues progesterone-stimulated signaling and GVBD in Msi AS treated oocytes, supporting our supposition that Musashi is mediating the processes that are specifically inhibited by Msi AS treatment. We have deleted the original luciferase reporter translation assays from Figure 3 and instead concentrate exclusively on the effects of Msi AS and Musashi rescue upon endogenous mRNA polyadenylation.
Figure 5: The new Musashi-specific rescue ( Figure 4 ) described above, would rule out the reviewer's prior concern that the Msi AS could be acting non-specifically to block general mRNA translation, accounting in the observed inability of cyclin B-∆87 to rescue polyadenylation ( Figure 5 ). Furthermore, Figure 3 (of both the previous and revised manuscripts) shows that progesterone-dependent translation of the Ringo protein is unaffected in Msi AS-treated oocytes. Taken together, the inability of the cyclin B-∆87 to rescue early class mRNAs is not simply attributable to a non-specific effect on general translation. These points have been clarified in the revised text. As requested by the reviewer, we have included data showing Msi AS-induced loss of polyadenylation of an additional Musashi-target mRNA lacking CPE sequences (TATABP2) in the revised Figure 3 .
Minor comments: At the reviewer's suggestion, we have revised our manuscript to place our findings in the greater context of the role of multiple trans-acting factors in the control of timing of gene expression during cell cycle progression, rather than stressing the weaknesses of a previous model. The missed citations have also been corrected.
As mentioned above, the mechanistic basis of the profound physiological effect caused by apparently minor fluctuations in the cellular pool of Musashi protein warrants further examination but this is outside the scope of the current study. Our discussion has been revised to acknowledge the role of the CPE combinational code in translational repression.
Reviewer 2
Figures 1/2: At the request of the reviewer we have added a time course analysis of translation of the cyclin B5 wild type (wt) and Musashi-binding mutant (mbm) reporter mRNAs to the revised Figure 2 (Figure 2D .). This data shows that loss of Musashi binding indeed results in loss of early (-GVBD) reporter polyadenylation. Under these conditions we do not see recovery of polyadenylation at late (GVBD +) time points, suggesting that translation of MBE-containing, early activated mRNAs is restricted to early activation. The restriction of translation of the cyclin B5 mRNA to early, cdc2-independent conditions is further indicated by the inability of injected cyclin B ∆87 to rescue translation in Msi AS-treated oocytes ( Figure 5B ). Conversely, conversion of a late CPE configuration in the cyclin B1 UTR does indeed change the timing of translation from late to early (Pique etal, 2008) . However, the cyclin B1 does contain an MBE and the mutational alteration to change the CPE configuration inadvertently added a second MBE. Our data with the cyclin B5 mRNA, would suggest that the MBE(s) directs the early translational activation of this modified cyclin B1 mRNA, while the new "early" CPE configuration in the mutant cyclin B1 UTR is simply permissive for MBE-directed early translational activation. These findings are discussed in the revised text. The reviewer pointed out that the reporter translation data should be presented in the context of timing per se rather than signaling-dependency. We have consequently deleted the signaling data (which utilized Mos AS) and have added time-specific reporter translation data ( Figures 2D, 2F & 2G). As described in our response to Reviewer 1 above, this new data clearly indicates that activation of the MBE mutant reporter is attenuated during early oocyte cell cycle progression. These data are consistent with a role for the Musashi-binding element in directing translational activation of the reporter during early progesterone-stimulated cell cycle progression.
Figures 3/4/5: The reviewer was concerned that the partial loss of Mos mRNA PCR product in Msi AS-injected oocytes might indicate that a proportion of the Mos mRNA was degraded, thus accounting for the observed loss of GVBD. We do observe a partial loss of early class, MBE-containing mRNAs in Msi AS injected oocytes (Figs 3, 4, 5 and Supp Fig. 7) . However, no such loss of late class mRNAs was observed in the same samples. We have added new data to the revised manuscript demonstrating that even when partial loss of early class Mos mRNA was observed, injection of exogenous Musashi to these Msi AS-treated oocytes results in rescue of polyadenylation of the Mos mRNA and recovery of progesterone-stimulated GVBD (Supplemental Figure 7) . This rescue data indicates that sufficient Mos mRNA is present in Msi AS-treated cells to support GVBD (Figure 4 ). As noted in response to Reviewer 1, Musashi may thus have a protective role in immature oocytes, but such a mechanism is outside the scope of the current study that focuses exclusively on mRNA translational activation in response to progesterone.
As also addressed in our response to Reviewer 1 above, we have deleted the data showing progesterone-stimulated accumulation of Musashi protein from Figure 3 and instead simply include the analysis of Msi AS-induced knockdown of Musashi protein levels in the supplementary section. The Musashi-specific rescue of Msi AS injected oocytes (which requires Musashi RNA binding activity) supports our supposition that Musashi is specifically mediating the processes that are inhibited upon Msi AS treatment. We have deleted the luciferase reporter translation assays from Figure 3 , and instead concentrate exclusively on the effects of Msi AS and Musashi rescue upon endogenous mRNA polyadenylation.
Minor comments: The annotation text and name errors have been corrected.
Reviewer 3:
Presentation of luciferase assay data: New data is presented showing the effect of inhibition of Musashi binding upon cyclin B5 reporter mRNA activation in response to progesterone in two independent experiments ( Figure 2F ). As described in our responses to Reviewers 1 and 2 above, this data shows quantified fold effects of each reporter in response to progesterone. In addition, we have included luciferase reporter assay data indicating that cyclin B5 reporter translation in response to progesterone is mediated through the polyadenylation ( Figure 2E ). We have deleted the luciferase assay data from the Msi AS experiments (Figure 3) , and instead concentrate exclusively on the effects of Msi AS upon endogenous mRNA polyadenylation.
Rescue of the Msi AS phenotype: We have included new data in the revised Figure 4 to demonstrate that expression of exogenous wild-type (but not RNA binding deficient) Musashi protein rescues progesterone-stimulated signaling and GVBD in Msi AS-treated oocytes. We also note that the Musashi rescue resulted in normal kinetics of progression through the cell cycle (Supplemental Figure 5 ) and translation of late, CPE-dependent mRNA translation (Figure 4 ). This Musashi-specific rescue greatly supports our supposition that Musashi is specifically mediating the processes that are inhibited upon Msi AS treatment.
Cyclin B2 polyadenylation data: The reviewer was correct in deducing that cdc2-independent cyclin B2 polyadenylation is Musashi-dependent. Likewise, our data indicate that polyadenylation of the late, cdc2-dependent cyclin B1 mRNA is also Musashi-dependent. In the revised manuscript we more clearly present our thesis that translation of late, cdc2-independent and cdc2-dependent mRNAs, are indirectly dependent upon Musashi via their dependence upon translation of early direct Musashi target mRNAs, such as Mos. We now include data (Supplementary Figure S1 ) that indicate that cyclin B2 is indeed Mos-independent and cdc2-independent, as reported by Pique etal.
Cyclin B5 mbm mutant: In the revised manuscript we include EMSA data demonstrating that the cyclin B5 mbm mutant does bind CPEB while the cyclin B5 CPE mutant does not ( Figure 2B ).
Role of CPEB in Mos synthesis: We have addressed the role of CPEB in early Mos mRNA translation in a previous study (Charlesworth etal 2002) wherein we show that a CPEB dominant negative mutant does not prevent the initial translation of the Mos mRNA prior to GVBD, but does attenuate the enhanced Mos accumulation upon completion of GVBD. In the revised discussion, we reiterate these findings in the context of the present study.
Minor points: Key data from the original supplementary figures has been moved to the paper as described above. The suggested corrections to the text have been made. The statement regarding the link between CPEB degradation and activation of cdc2-dependent mRNAs containing a CPE overlapping the polyadenylation hexanucleotide has been corrected. Of note, analysis of 14 characterized Xenopus early class mRNAs (defined by timing of polyadenylation prior to GVBD) indicates that 11/14 do indeed have an MBE (MacNicol, A.M. and MacNicol M.C., manuscript in preparation). Thank you for sending us your revised manuscript. Let me first of all apologise for the delay in getting back to you with a decision. Unfortunately we experienced difficulties with the availability of the referees at the time of resubmission. Our original referees have now finally seen the manuscript again, and you will be pleased to learn that in their view you have addressed their criticisms in a satisfactory manner, and that the paper will therefore be publishable in The EMBO Journal.
Before this will happen, however, I was wondering whether you would like to consider addressing the minor issues suggested by the referees (see below).
Please let us have a suitably amended manuscript as soon as possible.
Yours sincerely,
Editor
This manuscript which deals with the issue of temporal control if polyadenylation is much improved and benefits from the additional controls and redrafting of the manuscript. Referee #2 (Remarks to the Author):
The revised ms addresses my comments satisfactorily. Indeed, the extensive changes make for a substantially improved study
Largely minor textual points that would further improve the ms include 1. It would be useful to state the consensus CPE/MBE sequences in the Introduction 2. P 8. The fold activation by the cyclin B5 UTR in the reporter assay in eggs relative to oocytes is relatively modest -3x, compared to say cyclin B1 -50x or more. Can the authors comment? figure) is placed in the scheme alongside cyclin B1
7. P 17. Top paragraph, last line is not clear, nor is the mention of a second MBE in the preceding sentence -this should be shown in detail?
8. P 18. Top paragraph, second line starts with "curiously" -why?
Referee #3 (Remarks to the Author):
The manuscript is greatly improved and now suitable for publication. A thorough proof read of the manuscript is recommended, as there are multiple repeat mistakes, e.g. "polyadenyaltion" and "By contrast" instead of "In contrast". Please find attached our final revised version of the manuscript. At your suggestion, we have modified the text to address the minor issues raised by the reviewers. In particular we have addressed the behavior of the reporter mRNAs in Fig. 2 (revised manuscript page 9, last 2 sentences of the first paragraph and page 11, second paragraph, last sentence). We retain Fig. 2C as we feel it serves as an important control that would be buried in Supplementary data. The issue raised by reviewer 2 of the relative levels of the B5 and B1 reporters reflects the time at which the samples are prepared. However, since we do not present B1 translation data in the manuscript, I do not feel it is germane to the current study. I have spell checked the document to eliminate the typos identified by Reviewer 3.
